Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study

about

Th17/Treg immunoregulation and implications in treatment of sulfur mustard gas-induced lung diseases.

P2860

Q47585318-F1262D31-35B1-4591-BACE-11547542BF53

P2860

Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study

Item

http://www.wikidata.org/entity/Q35902505

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Interferon Beta-1a (AVONEX®) a ...... ospective, Observational Study

@ast

Interferon Beta-1a (AVONEX®) a ...... ospective, Observational Study

@en

type

Item

label

Interferon Beta-1a (AVONEX®) a ...... ospective, Observational Study

@ast

Interferon Beta-1a (AVONEX®) a ...... ospective, Observational Study

@en

prefLabel

Interferon Beta-1a (AVONEX®) a ...... ospective, Observational Study

@ast

Interferon Beta-1a (AVONEX®) a ...... ospective, Observational Study

@en

P1476

Interferon Beta-1a (AVONEX®) a ...... ospective, Observational Study

@en

P2093

Colin Wernsdörfer

http://www.w3.org/2001/XMLSchema#string

Gabriele Niemczyk

http://www.w3.org/2001/XMLSchema#string

Karin Rehberg-Weber

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials

Evidence for long-term use of intramuscular interferon beta-1a: an overview of relapse, disability, and MRI data from selected clinical trials

Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis

Possible clinical outcome measures for clinical trials in patients with multiple sclerosis

Cognitive performance in relapsing remitting multiple sclerosis: a longitudinal study in daily practice using a brief computerized cognitive battery.

Emerging methods for evaluating the effectiveness of intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis.

A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis

Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test.

The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force.

P304

15271-15286

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/IJMS160715271

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Christoph Kleinschnitz

P577

2015-07-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

279965657

http://www.w3.org/2001/XMLSchema#string

P698

26154767

http://www.w3.org/2001/XMLSchema#string

P932

4519899

http://www.w3.org/2001/XMLSchema#string

Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study

about

P2860

P2860

Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P932